Sellas life sciences group, inc. (SLS)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11
Cash flows from operating activities:
Net loss

-19,292

-27,670

-23,754

-

-

-

-

-

-

Net loss from continuing operations

-

-

-

-

-38,956

-28,284

-71,327

-33,325

-

Net loss

-

-

-

-17,681

-

-

-

-

-11,485

Adjustment to reconcile net loss to net cash used in operating activities:
Gain on extinguishment of debt

0

766

0

-201

-

-

-

-

-

Depreciation and amortization expense

-

-

-

3

107

86

286

49

163

Non-cash accretion of debt issuance costs

-

-

-

-

248

276

-

-

-

Non-cash In-process research and development impairment charge

2,833

9,100

0

-

-

-

-

-

-

Non-cash research and development expense

-

-

-

821

-

-

-

-

-

Non-cash interest expense

0

134

0

1,166

-

-

-

-

-

Amortization of research and development expense

-

-

258

-

-

-

-

-

-

Loss on disposal of equipment

-

-

-

-

-

-

-

-

-7

Gain on sale of marketable securities

-

-

-

-

-

-

3,911

0

0

Deferred income taxes

-95

-1,316

-

-41

365

-

1,052

-1,052

0

Non-cash stock-based compensation

573

395

3,169

354

1,931

4,666

2,307

1,394

3,001

Litigation settlement payable in common stock

-

-

-

-

1,000

0

0

-

-

Fair value of common stock issued in exchange for services

-

-

449

-

-

-

-

-

108

Litigation Settlement, Issuance of Common Stock, Value

-

-

0

-

-

-

-

-

-

Fair value of shares issued in exchange for research and development

-

-

-

1,974

-

-

-

-

-

Fair value of common stock issued in connection with litigation settlements

0

1,250

941

-

-

-

211

364

73

Change in fair value of common stock warrants

1,136

5,302

0

-

1,161

16,556

-44,001

-10,775

8,981

Change in fair value of contingent consideration

-586

-3,032

0

-

509

170

-926

-2,370

109

Loss on settlement of liability-classified warrants

0

727

0

-

-

-

-

-

-

Severance costs paid by Galena

-

-

1,900

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable

-

-

-

-

-

-

-

-

0

Inventories

-

-

-

-

-

-

-

-

0

Prepaid expenses and other assets

76

-212

-73

477

245

1,078

-437

396

99

Litigation settlement insurance recovery

-

-

-

-

21,700

0

0

-

-

Litigation settlement payable

-

-

-

-

-

-

0

-

-

Litigation settlement payable

-

-

-

-

24,000

0

-

-

-

Accounts payable

12

-7,936

8,366

-

-289

-21

-69

641

500

Accrued expenses and other current liabilities

-1,048

-2,282

-2,374

1,830

-3,593

4,044

2,811

-149

2,154

Net cash used in continuing operating activities

-

-

-

-

-38,802

-37,037

-23,276

-19,329

-

Loss from discontinued operations

-

-

-

-

-24,946

-8,322

5,351

1,644

-

Loss on sale of commercial assets

-

-

-

-

-4,549

0

0

-

-

Impairment charge from classification of assets held for sale

-

-

-

-

8,071

0

0

-

-

Changes in operating assets and liabilities attributable to discontinued operations

-

-

-

-

-2,968

-2,490

302

0

-

Net cash used in discontinued operating activities

-

-

-

-

-9,358

-5,832

-5,653

-1,644

-

Net cash used in operating activities

-17,643

-30,422

-10,989

-11,850

-48,160

-42,869

-28,929

-20,973

-14,668

Change in restricted cash

-

-

-

85

201

-

99

-

101

Cash paid for acquisition of Zuplenz rights

-

-

-

-

-

-

-

-

0

Cash paid for acquisition of GALE-401

-

-

-

-

0

2,415

0

0

-

Net cash acquired from acquisition of Galena

-

-

12,158

-

-

-

-

-

-

Purchase of short-term investments

-

-

-

-

-

-

-3,911

-

-

Cash received in Apthera acquisition

-

-

-

-

-

-

-

-

-168

Proceeds from sale of marketable securities

-

-

-

-

-

-

-

0

0

Cash paid for purchase of equipment and furnishings

-

-

-

-

153

57

320

-

53

Net cash used in continuing investing activities

-

-

-

-

-354

-2,472

3,492

0

-

Proceeds received from sale of commercial assets

-

-

-

-

11,283

0

0

-

-

Cash paid for commercial assets

-

-

-

-

534

3,056

15,532

-

-

Net cash used in discontinued investing activities

-

-

-

-

10,749

-3,056

-15,532

-87

-

Cash transferred with the RXi spin-off

-

-

-

-

-

-

-

-

0

Net cash used from investing activities

-

-

12,158

-85

10,395

-5,528

-12,040

-87

14

Cash flows from financing activities:
Proceeds from issuance of Series A convertible preferred stock and common stock warrants, net of issuance costs

0

9,647

0

-

-

-

-

-

-

Proceeds from issuance of common stock, net of offering costs

15,971

21,564

6,007

-

47,416

10,704

37,539

36,378

18,615

Fair value of liability-classified warrants issued in connection with Series A convertible preferred stock recorded as issuance cost

0

5,350

-

-

10,296

0

8,238

7,286

12,709

Deemed dividend arising from beneficial conversion feature of Series A convertible preferred stock

0

4,436

0

-

-

-

-

-

-

Repayment of interest and principal on long-term debt through issuance of common stock

0

3,721

0

-

0

0

-

-

-

Collection of stock subscription receivable

308

0

-

-

-

-

-

-

-

Cash paid for repurchase of warrants

-

-

-

-

-

-

-

266

0

Net proceeds from exercise of stock options

-

-

-

-

31

4,342

567

21

0

Proceeds from exercise of warrants

3,598

0

-

-

0

10,717

7,815

5,708

150

Dividends paid

0

487

0

-

-

-

-

-

-

Proceeds from common stock issued in connection with ESPP

-

-

-

-

-

-

-163

-93

-15

Proceeds from common stock issued in connection with Employee Stock Purchase Plan

-

-

-

-

309

263

-

-

-

Net proceeds from issuance of RXi convertible notes payable

-

-

-

-

-

-

-

-500

-500

Net proceeds from issuance of convertible debt

-

-

-

15,000

-

-

-

-

-

Change in restricted cash related to debt principal paid in common stock

-

-

-

1,500

0

0

9,865

0

0

Minimum cash covenant on long-term debt

-

-

-

-

0

0

-

-

-

Principal payments on long-term debt

0

7,601

473

-

3,911

1,766

-

-

-

Principal payments on long-term debt

-

-

-

-

-

-

0

0

-

Repayments of capital lease obligations

-

-

-

-

-

-

-

-

84

Net cash provided by financing activities

19,569

23,123

5,534

16,500

43,845

24,260

55,949

42,434

19,196

Net decrease in cash, cash equivalents, restricted cash, and restricted cash equivalents

1,926

-7,299

6,703

-

-

-

-

-

-

Net increase in cash and cash equivalents

-

-

-

4,565

6,080

-24,137

14,980

21,374

4,542

Supplemental disclosure of cash flow information:
Cash received during the periods for interest

118

186

0

-

18

15

19

1

2

Cash paid during the year for interest

0

321

0

-

-

-

-

-

-

Cash paid during the periods for interest

-

-

-

-

541

800

547

1

6

Supplemental disclosure of non-cash investing and financing activities:
Debt issued in connection with warrant exchange agreements

0

966

0

-

-

-

-

-

-

Deferred offering costs included in accounts payable and accrued expenses

135

0

-

-

-

-

-

-

-

Operating right of use asset and current and non-current liability

549

-

-

-

-

-

-

-

-

Reclassification of warrant liabilities upon exchange for shares of common stock

68

285

0

-

-

-

-

-

-

Impact of anti-dilution protection on liability-classified warrants

243

491

0

-

-

-

-

-

-

Fair value of warrants issued in connection with long-term debt recorded as debt issuance costs

-

-

-

-

0

0

-

-

-

Net liabilities distributed to common stock holders in the RXi spin-off, net of cash transferred

-

-

-

-

-

-

-

2,246

-

Net liabilities distributed to common stock holders in the RXi spin-off, net of cash transferred

-

-

-

-

-

-

-

-

0

Reclassification of warrant liabilities upon exercise

-

-

12,487

-

0

27,026

14,249

10,843

0

Fair value of options assumed in connection with acquisition of Galena

-

-

32

-

-

-

-

-

-

Related party payable settled in shares

-

-

228

-

-

-

-

-

-

Memorial Sloan Kettering Cancer Center payable settled in shares

-

-

150

-

-

-

-

-

-

Common stock issued in settlement of contingent purchase price consideration

-

-

-

-

-

-

1,247

1,579

0

Change in fair value of marketable securities before settlement

-

-

-

-

-

-

2,678

-2,678

0

Issuance of common stock in settlement of GALE-401 milestone

-

-

-

-

0

6,840

0

0

-3,120

Fair value of shares issued to acquire Zuplenz rights

-

-

-

-

0

2,500

0

0

-

Fair value of shares issued to acquire NeuVax

-

-

-

-

-

-

-

-

6,367

Future obligations for Zuplenz rights included in accrued expenses

-

-

-

-

0

2,716

0

0

6,460

Deemed dividend associated with conversion of 2015 Sely Note and common stock warrant issuance to Equilibria

-

-

675

-

-

-

-

-

-

Convertible Debt Two Thousand Fifteen Shareholder Notes
Stock issued

-

-

1,294

-

-

-

-

-

-

Convertible Debt Two Thousand Sely Note
Stock issued

-

-

6,064

-

-

-

-

-

-